Mark Leonard Singleton Sells 6,498 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) CFO Mark Leonard Singleton sold 6,498 shares of Bioventus stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total value of $66,214.62. Following the sale, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. This trade represents a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Mark Leonard Singleton also recently made the following trade(s):

• On Monday, December 23rd, Mark Leonard Singleton sold 10,733 shares of Bioventus stock. The shares were sold at an average price of $10.53, for a total value of $113,018.49.

Bioventus Stock Down 3.6 %

Shares of NYSE:BVS traded down $0.37 on Thursday, reaching $9.95. The company had a trading volume of 322,403 shares, compared to its average volume of 272,552. Bioventus Inc. has a 52-week low of $3.90 and a 52-week high of $14.38. The firm’s 50 day simple moving average is $10.37 and its 200-day simple moving average is $10.83. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a market capitalization of $807.44 million, a PE ratio of -16.31 and a beta of 0.85.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in Bioventus by 18.7% during the 4th quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company’s stock worth $25,852,000 after buying an additional 388,174 shares during the last quarter. Driehaus Capital Management LLC grew its stake in Bioventus by 33.7% during the 4th quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company’s stock worth $11,758,000 after buying an additional 282,341 shares during the last quarter. Geode Capital Management LLC grew its stake in Bioventus by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 940,496 shares of the company’s stock worth $11,241,000 after buying an additional 65,374 shares during the last quarter. American Century Companies Inc. grew its stake in Bioventus by 38.7% during the 4th quarter. American Century Companies Inc. now owns 884,673 shares of the company’s stock worth $9,289,000 after buying an additional 246,645 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Bioventus by 20.9% during the 4th quarter. Nuveen Asset Management LLC now owns 782,137 shares of the company’s stock worth $8,212,000 after buying an additional 135,236 shares during the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. Canaccord Genuity Group lifted their price target on Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and lifted their price target for the company from $12.00 to $13.00 in a report on Tuesday, December 17th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.